
Modalis Therapeutics Corporation
4883 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 中央区日本橋本町三丁目11番5号
- Website:
- https://modalistx.com/en/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Modalis Therapeutics Corporation is a Japanese biotechnology company at the forefront of epigenome editing, dedicated to revolutionizing the treatment of genetic disorders. Utilizing its proprietary CRISPR-GNDM® technology, Modalis offers a novel approach to selectively target and regulate gene expression without altering the underlying DNA sequence. This advancement allows for precise modifications to the epigenome, restoring balance and addressing various diseases. With a robust pipeline that includes both in-house and collaborative development strategies, the company focuses on creating therapeutics for conditions such as muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders. Committed to the belief that every life deserves attention, Modalis is poised to make significant contributions to the field of gene therapy.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-03-28 07:52 |
Inside Information Statement
臨時報告書
|
Japanese | 28.4 KB | |
2025-03-27 08:32 |
Internal Control over Financial Reporting
内部統制報告書-第9期(2024/01/01-2024/12/31)
|
Japanese | 24.1 KB | |
2025-03-27 08:30 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
2025-03-27 08:29 |
Annual Report
有価証券報告書-第9期(2024/01/01-2024/12/31)
|
Japanese | 2.1 MB | |
2025-02-21 07:31 |
Inside Information Statement
臨時報告書
|
Japanese | 21.5 KB | |
2024-08-13 08:14 |
Regulatory News Service
訂正有価証券届出書(組込方式)
|
Japanese | 293.9 KB | |
2024-08-13 07:58 |
Interim Report
半期報告書-第9期(2024/01/01-2024/12/31)
|
Japanese | 249.6 KB | |
2024-08-13 07:58 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
2024-08-07 08:01 |
Prospectus
有価証券届出書(組込方式)
|
Japanese | 495.2 KB | |
2024-05-14 06:00 |
Quarterly Report
四半期報告書-第9期第1四半期(2024/01/01-2024/03/31)
|
Japanese | 166.1 KB | |
2024-05-14 06:00 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
2024-04-05 08:51 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
2024-04-05 08:41 |
Regulatory News Service
訂正有価証券報告書-第8期(2023/01/01-2023/12/31)
|
Japanese | 1.3 MB | |
2024-03-29 06:29 |
Inside Information Statement
臨時報告書
|
Japanese | 28.0 KB | |
2024-03-27 06:40 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
Cuorips Inc. | Japan | 4894 | |
![]() |
Cyfuse Biomedical K.K. | Japan | 4892 | |
![]() |
DAIICHI SANKYO COMPANY, LIMITED | Japan | 4568 | |
![]() |
Daito Pharmaceutical Co., Ltd. | Japan | 4577 | |
![]() |
DanCann Pharma A/S | Denmark | DANCAN | |
![]() |
DARWIN AG | Germany | 7V0 | |
|
Dechra Pharmaceuticals PLC | United Kingdom | DPH | |
![]() |
Delta-Fly Pharma, Inc. | Japan | 4598 | |
|
Dermapharm Holding SE | Germany | DMP | |
![]() |
Dicot Pharma AB | Sweden | DICOTBT |